查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197405

左心耳市場增長、趨勢、COVID-19 影響和預測 (2023-2028)

Left Atrial Appendage Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，全球左心耳市場的複合年增長率預計為 20.1%。

主要亮點

  • COVID-19 的爆發對市場增長產生了前所未有的影響。 疫情導致各種心臟手術推遲或取消，影響了對左心耳的需求。 例如，歐洲 PMC 於 2021 年 7 月發表的一篇研究論文報告稱，2020 年 4 月至 2020 年 8 月期間在印度進行的心臟手術減少了 73%。 心臟手術的下降對市場增長產生了輕微的負面影響。 但是，由於封鎖的放鬆，這些推遲的手術已經進行。
  • 此外，COVID-19 還影響了人們的心臟健康，增加了對左心耳的需求。 由於這些因素，預計未來五年市場將繼續增長。
  • 市場增長的主要驅動力是老年人口的增加以及隨之而來的心血管疾病的增加。 此外，預計全球人口中房顫患病率的增加也將有助於市場增長。
  • 例如，根據美國國家生物技術信息中心 (NCBI) 的數據，2021 年 2 月全球房顫患病率為 375.74 億例（佔世界人口的 0.51%），與過去 20 年相比也有所增加減少 33% 至 預計全球人口中心房顫動情況的增加將推動預測期內研究市場的增長。
  • 65 歲以上的老年人患心房顫動等心血管疾病的風險也會增加，這會進一步導致心肌梗塞。 根據聯合國經濟和社會事務部（UDESA）的一份報告，到 2022 年，世界 65 歲及以上人口的比例預計將從 2022 年的 10% 上升到 2050 年的 16%。 因此，預計在預測期內，全球易患心血管疾病的老年人口增加將推動市場增長。
  • 此外，增加產品開發預計將有助於所研究市場的增長。 例如，2022 年 6 月，Conformal Medical Inc. 宣布招募其 CLAAS 系統的 CONFORM 關鍵試驗的第一名參與者。 第一批患者在美國的兩個地點登記。 CLAAS 系統旨在封閉非瓣膜性心房顫動 (Afib) 患者的左心耳 (LAA)，並在不使用抗凝劑的情況下降低中風風險。 Conformal Medical 表示，調查設備豁免 (IDE) 試驗的結果將有助於該設備獲得美國食品和藥物管理局 (FDA) 的上市前批准。
  • 因此，房顫患病率上升和創新產品開發預計將促進市場增長。 然而，設備的高成本可能會在預測期內抑制市場增長。

左心耳市場趨勢

預計在預測期內，左心耳附件市場將由醫院部門主導

  • 左心耳市場的醫院部分預計將出現顯著增長。 醫院數量的增加和基礎設施的進步，以及心房顫動等心血管疾病發病率的增加，預計將推動對左心耳的需求，並有助於研究領域的增長。
  • 此外，預計心房顫動負擔的增加將對這一細分市場產生重大影響。 根據 NCBI，房顫是最常見的心律失常。 隨著世界老齡化，房顫預計到 2050 年將影響美國的 6-1200 萬人，到 2060 年將影響歐洲的 1790 萬人。 2021 年 5 月發表的另一篇 NCBI 論文指出，北美、歐洲、中國和東南亞的房顫年齡和性別標準化患病率最高。
  • 還介紹說，房顫在中等收入國家的發病率是低收入國家的 7 倍，在高收入國家的發病率是低收入國家的 11 倍。 如此高的心房顫動和各種心血管疾病患病率也有望在預測期內推動研究領域的增長。
  • 此外，預計醫院數量的增加也將促進所研究細分市場的增長。 例如，美國醫院協會（AHA）2022年發布的統計數據顯示，2022年美國活躍醫院總數為6093家，入□□院人數為33356853人次。 因此，大量醫院推動了對左心耳的需求增加，從而推動了研究領域的增長。
  • 因此，醫院數量的增加和對晚期左心耳的需求增加等因素預計將增加該細分市場對左心耳的需求，從而推動該細分市場的增長。 .

預計北美將佔據很大的市場份額，預計在預測期內也會如此

  • 由於心房顫動病例不斷增加，預計北美將成為左心附件市場的重要區域。 此外，由於技術的快速引入，主要市場參與者的出現和先進產品的推出也有望促進市場的增長。
  • 根據美國疾病控制與預防中心 (CDC) 的數據（2022 年 10 月），到 2030 年，美國預計將有 1210 萬人患有房顫。 2021 年 7 月發布的一項類似的 NCBI 分析發現，墨西哥 8,686 名患者中有 498 名患有心房顫動，男性和老年女性的患病率更高。 此外，隨著老年人口的增加，未來研究目標市場的需求有望擴大。 左心房附件管理至關重要，因為心房顫動很可能導致心肌梗塞。 此外，新技術正在被引入市場，增加了這些設備的採用。
  • 此外，預計老齡化人口的增加將推動北美國家/地區的市場增長。 例如，根據加拿大統計局 2022 年 8 月發布的數據，加拿大 70-74 歲的人口有 1,847,585 人，而 80-84 歲的人口為 840,545 人。 預計易患此類心血管疾病的老齡化人口增加將推動對左心耳的需求並促進市場增長。
  • 該國主要參與者的存在、技術進步和有利的產品批准將促進美國研究市場的增長。 例如，2021 年 8 月，雅培（Abbott）公司的左心房附件封閉 Amplatzer Amulet 獲得 FDA 批准，用於治療有缺血性中風風險的心房顫動。 該設備可立即關閉心房顫動患者的左心耳（血栓形成部位），從而降低中風風險並消除對抗凝血劑的直接需求。
  • 因此，心血管疾病負擔增加、老年人口增加、主要市場參與者的存在以及產品開發等因素預計將促進該地區的市場增長。

左心耳市場的競爭對手分析

由於多家公司在全球和區域運營，左心耳市場在本質上是分散的。 預計將主導左心耳市場的主要公司包括 Abbott、Articure、Boston Scientific、Johnson and Johnson、Lifetech Scientific、Occlutech、Cardia Inc。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 心房顫動的負擔增加
    • 設備的技術進步
  • 市場製約因素
    • 設備成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：單位：百萬美元）

  • 按產品分類
    • 心內膜
    • 心外膜
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 世界其他地區

第六章競爭格局

  • 公司簡介
    • Abbott
    • Articure
    • Boston Scientific
    • Johnson & Johnson（Biosense Webster）
    • Lifetech Scientific
    • Occlutech
    • Cardia Inc
    • Aegis Medical Group
    • Acutus Medical Inc
    • ONOCOR Llc

第7章 市場機會今後動向

簡介目錄
Product Code: 70653

The global left atrial appendage devices market is expected to register a CAGR of 20.1% during the forecast period.

Key Highlights

  • The COVID-19 outbreak had an unprecedented impact on the growth of the market. This outbreak resulted in the postponement and cancellation of various cardiac surgeries, affecting the demand for left atrial appendage devices. For instance, a research article published by Europe PMC in July 2021 reported a 73% decrease in cardiac procedures performed in India between April and August 2020. Such reduction in cardiac procedures had a slight negative impact on the market's growth. However, with the relaxation of the lockdown, these postponed surgeries were carried out.
  • Additionally, COVID -19 has also impacted people's cardiac health, increasing the demand for left atrial appendage devices. Thus, owing to these factors, the studied market is expected to continue its growth over the coming five years.
  • The key contributors to the market growth are the increasing geriatric population and associated cardiovascular diseases. Also, the rise in atrial fibrillation among the global population is expected to contribute to the market's growth.
  • For example, according to the National Center for Biotechnology Information (NCBI), in February 2021, the worldwide prevalence of atrial fibrillation was 37,574 million cases (0.51% of the world's population), which also increased by 33% during the last 20 years. Such an increase in atrial fibrillation conditions among the global population is expected to drive the growth of the studied market during the forecast period.
  • Moreover, people aged 65 years and above are at a higher threat of causing cardiovascular diseases such as atrial fibrillation, which might further lead to heart stroke. According to the UN Department of Economic and Social Affairs (UDESA) report, 2022, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Thus, the increase in the global geriatric population prone to cardiovascular diseases is expected to drive the market's growth during the forecast period.
  • Furthermore, increasing product developments are expected to contribute to the growth of the studied market. For instance, in June 2022, Conformal Medical Inc. announced the enrolment of the first participants in the CONFORM pivotal trial of its CLAAS System. The first patients were enrolled at two sites in the US. The CLAAS System has been designed to seal the left atrial appendage (LAA) in non-valvular atrial fibrillation (Afib) patients to reduce stroke risk without using anticoagulants. Conformal Medical noted that the findings from the investigational device exemption (IDE) study will help the company seek pre-market approval for the device from the US Food and Drug Administration (FDA ).
  • Therefore, the increasing prevalence of atrial fibrillation and innovative product developments are expected to contribute to the market's growth. However, the high cost of devices may restrain the growth of the market during the forecast period.

Left Atrial Appendage Devices Market Trends

Hospital Segment is Expected to Hold a Significant Share in the Left Atrial Appendage Devices Market Over the Forecast Period

  • The hospital segment of the left atrial appendage devices market is expected to show significant growth. The increasing number of hospitals and advancing infrastructure, coupled with the increasing incidence of cardiovascular disorders such as atrial fibrillation, are expected to drive the demand for left atrial appendage devices, thereby contributing to the growth of the studied segment.
  • Furthermore, the increasing burden of atrial fibrillation is expected to be a significant contributor to this segment. According to the NCBI, atrial fibrillation is the most frequent cardiac arrhythmia. As the population ages globally, atrial fibrillation (AF) is predicted to affect 6-12 million people in the USA by 2050 and 17.9 million in Europe by 2060. Also, another NCBI article published in May 2021 mentioned that age and gender-standardized prevalence of atrial fibrillation was highest in North America, Europe, China, and South East Asia.
  • The report also mentioned that compared with low-income countries, atrial fibrillation was 7-fold higher in middle-income countries and 11-fold higher in high-income countries. Such a high prevalence of atrial fibrillation and various cardiovascular disorders is also expected to drive the growth of the studied segment over the forecast period.
  • Additionally, the increasing number of hospitals is also expected to contribute to the growth of the studied segment. For instance, the American Hospital Association (AHA) statistics published in 2022 show that the total number of active hospitals in the United States was 6,093 in 2022, with 33,356,853 hospital admissions. Thus, the high volume of hospitals drives increased demand for left atrial appendage devices, thereby boosting the studied segment growth.
  • Hence, factors such as the increasing number of hospitals and increasing demand for advanced left atrial appendage devices are expected to increase the demand for left atrial appendage devices in this segment and thus drive the market segment's growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

  • North America is expected to be a dominant region in the left atrial appendage devices market owing to the growing number of cases of atrial fibrillation. Additionally, the launch of advanced products with the presence of major market players and quick adoption of the technologies are also expected to contribute to the market's growth.
  • According to Centre for Disease Control and Prevention (CDC) data, October 2022, it is predicted that 12.1 million people in the United States will have atrial fibrillation by the year 2030. According to a similar NCBI analysis released in July 2021, atrial fibrillation was discovered in 498 of the 8,686 patients in the Mexican population, with a higher prevalence in men and older women. Also, with the rising geriatric population, the demand for the studied market is expected to grow in the future. Atrial fibrillation is likely to cause heart stroke, so left atrial appendage management is of utmost importance. Furthermore, novel technologies are being introduced in the market, increasing the adoption of these devices.
  • Additionally, the rising geriatric population is expected to drive the market's growth in North American countries. For instance, the data published by Statistics Canada in August 2022 indicated that the population aged 70 to 74 years in Canada was 1,847,585, whereas the population aged 80 to 84 years was 840,545. Such a rise in the geriatric population prone to developing cardiovascular diseases is expected to drive the demand for left atrial appendage devices, thereby contributing to the market's growth.
  • The presence of key players in the country, technological advancements, and the availability of favorable product approvals augment the growth of the market studied in the United States. For instance, in August 2021, Abbott received approval from the FDA for its Amplatzer Amulet left atrial appendage occluder to treat the device with atrial fibrillation at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage - an area where blood clots can form in people suffering from atrial fibrillation - reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.
  • Thus, factors such as the increasing burden of cardiovascular disorders, the growing geriatric population, the presence of major market players, and product developments are expected to contribute to the market growth in this region.

Left Atrial Appendage Devices Market Competitor Analysis

The left atrial appendage devices market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Key players that are expected to be dominant in left atrial appendage devices market are Abbott, Articure, Boston Scientific, Johnson and Johnson, Lifetech Scientific, Occlutech, Cardia Inc., among others

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Atrial Fibrillation
    • 4.2.2 Technological Advancements in the Devices
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Endocardial
    • 5.1.2 Epicardial
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centres
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Articure
    • 6.1.3 Boston Scientific
    • 6.1.4 Johnson & Johnson (Biosense Webster)
    • 6.1.5 Lifetech Scientific
    • 6.1.6 Occlutech
    • 6.1.7 Cardia Inc
    • 6.1.8 Aegis Medical Group
    • 6.1.9 Acutus Medical Inc
    • 6.1.10 ONOCOR Llc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS